Open AccessAtezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Author(s) -
Jens Huober,
Carlos H. Barrios,
Naoki Niikura,
Michał Jarząb,
YuanChing Chang,
Shan Leigh Huggins-Puhalla,
José Luiz Pedrini,
Lyudmila Zhukova,
Vilma Graupner,
Daniel Eiger,
Volkmar Henschel,
N Gochitashvili,
Chiara Lambertini,
Eleonora Restuccia,
Hong Zhang
Publication year - 2022
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.21.02772
Subject(s) - atezolizumab , medicine , oncology , placebo , trastuzumab , adverse effect , breast cancer , chemotherapy , taxane , phases of clinical research , cancer , gastroenterology , surgery , immunotherapy , pathology , pembrolizumab , alternative medicine
Combining standard of care (pertuzumab-trastuzumab [PH], chemotherapy) with cancer immunotherapy may potentiate antitumor immunity, cytotoxic activity, and patient outcomes in high-risk, human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We report the phase III IMpassion050 primary analysis of neoadjuvant atezolizumab, PH, and chemotherapy in these patients.